Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10875)
  2. Meeting Abstract (9462)
  3. Review (551)
  4. Book Section (417)
  5. Editorial (334)
  6. Guidelines (157)
  7. Correspondence (116)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22137)
  2. GSK Faculty (5903)
  3. Genitourinary Oncology Service (5632)
  4. Survivorship Research (5205)
  5. Gastrointestinal Oncology Service (4671)
  6. Breast Medicine Service (4120)

More Groups

People
  1. Robert Motzer (1246)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (870)
  6. Leonard Saltz (791)

More People

Years
  1. 2025 (540)
  2. 2024 (1384)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5253)
  2. Annals of Oncology (1295)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (772)
  5. Journal of Thoracic Oncology (531)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5544)
  2. Elsevier Inc. (2654)
  3. American Association for Cancer Research (2322)
  4. Oxford University Press (1812)
  5. Nature Publishing Group (1030)
  6. Springer (979)

More Publishers

Results (22159)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A Multicenter, open-label phase 1/2 study of TYRA 300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 gene alterations (SURF301)
    Meeting Abstract

    Zhang, A.; Boni, V.; Hanson, A.; Mantia, C.; Weickhardt, A.; Yu, E.; Gupta, S.; Robert, M.; Iyer, G.; Millward, M.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • First clinical results from a phase 1 trial of PRT3789, a first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4
    Meeting Abstract

    Yap, T. A.; Dowlati, A.; Dagogo-Jack, I.; Vibert, J.; Spira, A. I.; Moreno Garcia, V.; Punekar, S. R.; Calvo, E.; Sonpavde, G. P.; Awad, M.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal or bone metastases in the phase II VISION trial
    Meeting Abstract

    Gasking, S.; Reinmuth, N.; Mazieres, J.; Popat, S.; Paz-Ares, L.; Hook, E.; Hatswell, A.; Vlassak, S.; Johne, A.; Vioix, H.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Longer-term safety and efficacy of selinexor maintenance therapy for patients with TP53wt advanced or recurrent endometrial cancer: Follow-up subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
    Meeting Abstract

    Haluska, P.; Pérez-Fidalgo, J. A.; Vergote, I.; Hamilton, E.; de Giorgi, U.; Van Gorp, T.; Lübbe, K.; Zikan, M.; Helpman, L.; Miller, D. S.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy of selpercatinib by RET fusion partner in RET+ NSCLC: Results from the LIBRETTO-001 and LIBRETTO-431 trials
    Meeting Abstract

    Solomon, B.; Drilon, A.; Park, K.; Novello, S.; Nadal, E.; Besse, B.; Peled, N.; Peterson, P.; Barker, S.; Szpurka, A. M.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, randomized, placebo-controlled, double-blind, multicenter trial of Selinexor in maintenance therapy for patients with p53 wild-type, advanced or recurrent endometrial carcinoma
    Meeting Abstract

    Webber, K.; Vergote, I.; Mirza, M. R.; Coleman, R.; Fidalgo, J. A. P.; Monk, B. J.; Valabrega, G.; Slomovitz, B.; Van Gorp, T.; Moore, K.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Updated tumor agnostic efficacy of selpercatinib in patients with RET fusion-positive solid tumors: LIBRETTO-001
    Meeting Abstract

    Ohe, Y.; Subbiah, V.; Sukrithan, V.; Robinson, B.; Deschler-Baier, B.; Iwasa, T.; Ohashi, K.; Goto, K.; Nishio, M.; Satouchi, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Clinical and biomarker data from a phase 1/2 trial of ifinatamab deruxtecan (I-DXd; DS-7300) in advanced solid tumors
    Meeting Abstract

    Doi, T.; Patel, M. R.; Koyama, T.; Falchook, G. S.; Friedman, C.; Piha-Paul, S. A.; Gutierrez, M.; Awad, M.; Mattour, A.; Satoh, T.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Final OS analysis from the phase 3 TROPiCS-02 study: sacituzumab govitecan in HR+/HER2 - metastatic breast cancer
    Meeting Abstract

    Rugo, H. S.; Bardia, A.; Marme, F.; Cortes, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E.; Dalenc, F.; Pardo, P. G.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Assessing 2024 oncology advances and looking ahead
    Editorial

    Iyengar, N. M.
    Oncology (Norwalk) (2024)

    Fulltext@MSK | Save